Endece - Regulating BioSwitch Pathways

CorporateProductsMedia & PressPublicationContact Us
  • Contact Endece

Site Map

Home
Corporate
· About Endece
· History
· Corporate Compliance
· Corporate Strategy
· Management
· Scientific Advisory Board
· Network

 

Products
· Drug Pipeline
· Patent Estate
Media & Press
Publication
Contact Us

Dr. James Yarger

Dr. James Yarger

“Previous experience taught me the hard way that one should not attempt to start a business, especially in science, unless you are working with only the very best of the best.”

Ms. Jean Yarger

Ms. Jean Yarger

Our business collaborative model includes supportive investors, experienced management team and respected advisors all focused on the discovery and development of new drug concepts; EN-DE-CE.

Dr. James Yarger

Dr. James Yarger

“Our recent discovery, that ENDECE’s proprietary library of structurally related small molecules can dramatically influence the outcome of estrogen receptor activation, is leading to new ways to treat human diseases including cancer.”

Dr. James Yarger

Dr. James Yarger

“The human body regulates it’s self via biological pathways. The ENDECE concept is to modulate these naturally occurring pathways to control and stop the progression of disease.”

Dr. Steve Nye

Dr. Steve Nye

“Our data suggests that ENDECE’s lead drug, NDC-1308, effectively activates biological pathways that normally kill damaged cells but are evaded by tumor cells.”

Dr. James Yarger

Dr. James Yarger

“Total confidence in our novel approach to rational drug design and focused early development utilizing the best talent and latest technology we can find is our strategy for success.”

Dr. Steve Nye

Dr. Steve Nye

“ENDECE’s drug discovery efforts that started with modeling nuclear receptor ligand binding domains have led to an in-house library of new and proprietary compounds.”

Dr. Steve Weitman

Dr. Steve Weitman

“Preclinical efforts that characterized NDC-1308’s mechanism of action at the molecular level will serve as a bridge to clinical studies and potentially reveal relevant biomarkers.”

Dr. James Yarger

Dr. James Yarger

“We are ecstatic with our success in harnessing the biological activities directed by estrogen receptors in new ways to treat human diseases including cancer.”

Dr. Steve Nye

Dr. Steve Nye

“Preclinical studies, performed by our network of expert collaborators, have enabled insight into NDC-1308’s mechanism of action at the molecular level along with proof of principal in established animal models.”

Dr. Steve Nye

Dr. Steve Nye

“ENDECE’s drug discovery efforts that started with modeling nuclear receptor ligand binding domains have led to an in-house library of new and proprietary compounds.”

Dr. Victor Vogel

Dr. Victor Vogel

“What appealed to me was that it was such a novel, different, creative strategy. Either this is going to be a total bust or something very interesting.”

Mr. Jim Cederna

Mr. Jim Cederna

“ENDECE’s leaders have years of experience building new high tech businesses which I expect will be hugely successful.”

Contact Us

ENDECE
1001 W. Glen Oaks Lane
Suite 105B
Mequon, WI 53092
Ph: 262-240-9690
Fax: 262-240-9693